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Sir, C l o z a p i n e re m a i n s t h e d r u g o f c h o i c e f o r treatment-resistant schizophrenia and useful anti-suicidal and anti-aggressive medication in patients with schizophrenia and other psychotic disorders. It has also shown benefits for treatment of tardive dyskinesia and psychosis in patients with Parkinson's disease. [1] Clozapine-induced agranulocytosis is a rare adverse drug event that occurs in 1% of treated individuals and can be fatal if not detected early. As a result, clozapine is underused despite its superior efficacy. [2] Previous U.S Food and Drug Administration (FDA) guideline for monitoring agranulocytosis in patient's on clozapine [3] recommended that both white blood cell (WBC) count and absolute neutrophil count (ANC) should be done.
On September 2015, the U.S FDA [4] announced changes to the requirements for monitoring, prescribing, dispensing, and receiving clozapine, to address continuing safety concerns and current knowledge about neutropenia. These changes are being made to address continuing concerns and current knowledge about neutropenia.
These changes include:
• FDA has clarified and enhanced the prescribing information for clozapine that explains how to monitor patients for neutropenia and manage clozapine treatment. In addition, the agency announced a new, shared risk evaluation and mitigation strategy (REMS) called the clozapine REMS program to improve the monitoring and management of patients with severe neutropenia. This program, which will require prescribers, pharmacies, and patients to enroll in a single centralized program, replaces the six existing clozapine registries maintained by individual clozapine manufacturers • Neutropenia will now be monitored by the ANC only, rather than in conjunction with the WBC count • Treatment should be interrupted if neutropenia is suspected to be clozapine-induced for ANC < 1000 cells per microliter. The requirements for ANC are modified so that patients will be able to continue clozapine treatment with a lower ANC a change that will allow continued treatment for a greater number of patients • Patients with benign ethnic neutropenia (BEN) (ethnic groups who have low counts even before they start the treatment), who previously were not eligible for clozapine treatment, will now also be able to receive the medicine. For patients with BEN, treatment should be interrupted if neutropenia is suspected to be clozapine-induced for ANC < 500 cells per microliter
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• The FDA says although rechallenging patients who develop severe neutropenia during treatment with clozapine is not recommended, under the revised prescribing information, prescribers will have more flexibility to make individualized treatment decisions for their patients if they determine that the risk of psychiatric illness is greater than the risk of recurrent severe neutropenia, especially in patients for whom clozapine may be antipsychotic of last resort.
New FDA guidelines allow for more clinical flexibility and shared decision making than the more absolute structure of the older system.
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